Biophytis S.A.

Report Publication Announcement • Sep 20, 2017

Press Release

Biophytis to participate in upcoming industry and investors conferences

Paris (France), September 20th , 2017, 6pm – BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, will participate in the upcoming weeks to key industry events in Shanghai, Boston and Berlin as well as key investor events in Paris and Geneva.

Industry events:

• The French Health-Tech Tour in China, September 25 in Shanghai
• The 10th annual international partnering conference Biopharm America 2017, September 26-27 in Boston
• The 23rd annual international partnering conference Bio-Europe, November 6-8 in Berlin

Investors' events:

• The European Large & Midcap event, October 4-5, in Paris
• The Geneva European Midcap event, November 28-29, in Geneva

****

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat Sarcopenia, and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.

The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).

For more information: http://www.biophytis.com

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

BIOPHYTIS Stanislas VEILLET CEO contact@biophytis.com Tel: +33 (0) 1 41 83 66 00 Citigate Dewe Rogerson Presse internationale & Investisseurs Laurence BAULT/Antoine DENRY Laurence.bault@citigate.fr/antoine.denry@citigate.fr Tel: +33 (0)1 53 32 84 78 Mob: +33(0)6 64 12 53 61

LifeSci Advisors Chris MAGGOS Managing Director, Europe chris@lifesciadvisors.com Tel: +41 79 367 6254